1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Bn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Bn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Vaccine Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Bn) Analysis By Vaccine Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Vaccine Type, 2022-2032
5.3.1. Monovalent Vaccines
5.3.2. Multivalent Vaccines
5.4. Y-o-Y Growth Trend Analysis By Vaccine Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Vaccine Type, 2022-2032
6. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Bn) Analysis By Indication, 2017-2021
6.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Indication, 2022-2032
6.3.1. Influenza
6.3.2. Measles, Mumps & Rubella (MMR)
6.3.3. Polio
6.3.4. Chickenpox
6.3.5. Shingles
6.3.6. Rotavirus
6.3.7. Other Indications
6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021
6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032
7. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Bn) Analysis By Route of Administration, 2017-2021
7.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Route of Administration, 2022-2032
7.3.1. Intramuscular
7.3.2. Subcutaneous
7.3.3. Oral
7.3.4. Intranasal
7.3.5. Intravenous
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032
8. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Age Group
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Bn) Analysis By Age Group, 2017-2021
8.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By Age Group, 2022-2032
8.3.1. Pediatric
8.3.2. Adolcents
8.3.3. Adults
8.3.4. Geriatric
8.4. Y-o-Y Growth Trend Analysis By Age Group, 2017-2021
8.5. Absolute $ Opportunity Analysis By Age Group, 2022-2032
9. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Bn) Analysis By End User, 2017-2021
9.3. Current and Future Market Size Value (US$ Bn) Analysis and Forecast By End User, 2022-2032
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021
9.5. Absolute $ Opportunity Analysis By End User, 2022-2032
10. Global Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Bn) Analysis By Region, 2017-2021
10.3. Current Market Size Value (US$ Bn) Analysis and Forecast By Region, 2022-2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. MEA
10.4. Market Attractiveness Analysis By Region
11. North America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Value (US$ Bn)ed States
11.2.1.2. Canada
11.2.2. By Vaccine Type
11.2.3. By Indication
11.2.4. By Route of Administration
11.2.5. By Age Group
11.2.6. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Vaccine Type
11.3.3. By Indication
11.3.4. By Route of Administration
11.3.5. By Age Group
11.3.6. By End User
11.4. Key Takeaways
12. Latin America Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Vaccine Type
12.2.3. By Indication
12.2.4. By Route of Administration
12.2.5. By Age Group
12.2.6. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Vaccine Type
12.3.3. By Indication
12.3.4. By Route of Administration
12.3.5. By Age Group
12.3.6. By End User
12.4. Key Takeaways
13. Europe Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. U.K.
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Europe
13.2.2. By Vaccine Type
13.2.3. By Indication
13.2.4. By Route of Administration
13.2.5. By Age Group
13.2.6. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Vaccine Type
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Age Group
13.3.6. By End User
13.4. Key Takeaways
14. East Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Vaccine Type
14.2.3. By Indication
14.2.4. By Route of Administration
14.2.5. By Age Group
14.2.6. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Vaccine Type
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Age Group
14.3.6. By End User
14.4. Key Takeaways
15. South Asia Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
15.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
15.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
15.2.1. By Country
15.2.1.1. India
15.2.1.2. ASEAN
15.2.1.3. Rest of South Asia
15.2.2. By Vaccine Type
15.2.3. By Indication
15.2.4. By Route of Administration
15.2.5. By Age Group
15.2.6. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Vaccine Type
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Age Group
15.3.6. By End User
15.4. Key Takeaways
16. Oceania Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
16.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
16.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
16.2.1. By Country
16.2.1.1. Australia
16.2.1.2. New Zealand
16.2.2. By Vaccine Type
16.2.3. By Indication
16.2.4. By Route of Administration
16.2.5. By Age Group
16.2.6. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Vaccine Type
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Age Group
16.3.6. By End User
16.4. Key Takeaways
17. MEA Attenuated Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Country
17.1. Historical Market Size Value (US$ Bn) Trend Analysis By Market Taxonomy, 2017-2021
17.2. Market Size Value (US$ Bn) Forecast By Market Taxonomy, 2022-2032
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of MEA
17.2.2. By Vaccine Type
17.2.3. By Indication
17.2.4. By Route of Administration
17.2.5. By Age Group
17.2.6. By End User
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Vaccine Type
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Age Group
17.3.6. By End User
17.4. Key Takeaways
18. Key Countries Attenuated Vaccines Market Analysis
18.1. Value (US$ Bn)ed States
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2021
18.1.2.1. By Vaccine Type
18.1.2.2. By Indication
18.1.2.3. By Route of Administration
18.1.2.4. By Age Group
18.1.2.5. By End User
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2021
18.2.2.1. By Vaccine Type
18.2.2.2. By Indication
18.2.2.3. By Route of Administration
18.2.2.4. By Age Group
18.2.2.5. By End User
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2021
18.3.2.1. By Vaccine Type
18.3.2.2. By Indication
18.3.2.3. By Route of Administration
18.3.2.4. By Age Group
18.3.2.5. By End User
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2021
18.4.2.1. By Vaccine Type
18.4.2.2. By Indication
18.4.2.3. By Route of Administration
18.4.2.4. By Age Group
18.4.2.5. By End User
18.5. Rest of Latin America
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2021
18.5.2.1. By Vaccine Type
18.5.2.2. By Indication
18.5.2.3. By Route of Administration
18.5.2.4. By Age Group
18.5.2.5. By End User
18.6. Germany
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2021
18.6.2.1. By Vaccine Type
18.6.2.2. By Indication
18.6.2.3. By Route of Administration
18.6.2.4. By Age Group
18.6.2.5. By End User
18.7. U.K.
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2021
18.7.2.1. By Vaccine Type
18.7.2.2. By Indication
18.7.2.3. By Route of Administration
18.7.2.4. By Age Group
18.7.2.5. By End User
18.8. France
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2021
18.8.2.1. By Vaccine Type
18.8.2.2. By Indication
18.8.2.3. By Route of Administration
18.8.2.4. By Age Group
18.8.2.5. By End User
18.9. Spain
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2021
18.9.2.1. By Vaccine Type
18.9.2.2. By Indication
18.9.2.3. By Route of Administration
18.9.2.4. By Age Group
18.9.2.5. By End User
18.10. Italy
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2021
18.10.2.1. By Vaccine Type
18.10.2.2. By Indication
18.10.2.3. By Route of Administration
18.10.2.4. By Age Group
18.10.2.5. By End User
18.11. Rest of Europe
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2021
18.11.2.1. By Vaccine Type
18.11.2.2. By Indication
18.11.2.3. By Route of Administration
18.11.2.4. By Age Group
18.11.2.5. By End User
18.12. China
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2021
18.12.2.1. By Vaccine Type
18.12.2.2. By Indication
18.12.2.3. By Route of Administration
18.12.2.4. By Age Group
18.12.2.5. By End User
18.13. Japan
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2021
18.13.2.1. By Vaccine Type
18.13.2.2. By Indication
18.13.2.3. By Route of Administration
18.13.2.4. By Age Group
18.13.2.5. By End User
18.14. South Korea
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2021
18.14.2.1. By Vaccine Type
18.14.2.2. By Indication
18.14.2.3. By Route of Administration
18.14.2.4. By Age Group
18.14.2.5. By End User
18.15. India
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2021
18.15.2.1. By Vaccine Type
18.15.2.2. By Indication
18.15.2.3. By Route of Administration
18.15.2.4. By Age Group
18.15.2.5. By End User
18.16. ASEAN
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2021
18.16.2.1. By Vaccine Type
18.16.2.2. By Indication
18.16.2.3. By Route of Administration
18.16.2.4. By Age Group
18.16.2.5. By End User
18.17. Rest of South Asia
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2021
18.17.2.1. By Vaccine Type
18.17.2.2. By Indication
18.17.2.3. By Route of Administration
18.17.2.4. By Age Group
18.17.2.5. By End User
18.18. Australia
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2021
18.18.2.1. By Vaccine Type
18.18.2.2. By Indication
18.18.2.3. By Route of Administration
18.18.2.4. By Age Group
18.18.2.5. By End User
18.19. New Zealand
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2021
18.19.2.1. By Vaccine Type
18.19.2.2. By Indication
18.19.2.3. By Route of Administration
18.19.2.4. By Age Group
18.19.2.5. By End User
18.20. GCC Countries
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2021
18.20.2.1. By Vaccine Type
18.20.2.2. By Indication
18.20.2.3. By Route of Administration
18.20.2.4. By Age Group
18.20.2.5. By End User
18.21. South Africa
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2021
18.21.2.1. By Vaccine Type
18.21.2.2. By Indication
18.21.2.3. By Route of Administration
18.21.2.4. By Age Group
18.21.2.5. By End User
18.22. Israel
18.22.1. Pricing Analysis
18.22.2. Market Share Analysis, 2021
18.22.2.1. By Vaccine Type
18.22.2.2. By Indication
18.22.2.3. By Route of Administration
18.22.2.4. By Age Group
18.22.2.5. By End User
18.23. Rest of MEA
18.23.1. Pricing Analysis
18.23.2. Market Share Analysis, 2021
18.23.2.1. By Vaccine Type
18.23.2.2. By Indication
18.23.2.3. By Route of Administration
18.23.2.4. By Age Group
18.23.2.5. By End User
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Vaccine Type
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Age Group
19.3.6. By End User
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. GlaxoSmithKline
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Merck
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Pfizer
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. Sanofi
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. Astellas Pharma
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Johnson and Johnson
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. CSL
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. Serum Institute Of India
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology